

NEW HORIZONS

Priorities for Treatment Intensification in Managing HSPC



Sunday 15 September 2024 | 13:00–14:30 CEST
Valencia Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain



Professor
Eleni Efstathiou
USA (Chair)



Professor
Stephen Freedland
USA



Doctor
Alejo Rodríguez-Vida
Spain



Professor
Thomas Steuber
Germany

Agenda

Time	Session	Speaker(s)
13:00–13:05	Welcome and introduction	Prof. Eleni Efstathiou (Chair)
13:05–13:20	The importance of early treatment intensification in patients with nmHSPC and high-risk BCR	Prof. Stephen Freedland
13:20–13:25	Q&A and panel discussion	All Faculty
13:25–13:40	Practical considerations when selecting patients with high-risk BCR	All Faculty
13:40–13:55	The importance of early treatment intensification in patients with mHSPC	Dr. Alejo Rodríguez-Vida
13:55–14:05	Q&A and panel discussion	All Faculty
14:05–14:20	Maximising QoL for patients with HSPC	Prof. Thomas Steuber
14:20–14:25	Q&A and panel discussion	All Faculty
14:25–14:30	Summary and meeting close	Prof. Eleni Efstathiou (Chair)

BCR, biochemical recurrence; HSPC, hormone-sensitive prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; nmHSPC, non-metastatic hormone-sensitive prostate cancer; PSADT, prostate-specific antigen doubling time; QoL, quality of life.

This symposium is fully funded and organised by Astellas, including speaker honoraria and production of materials. It is intended for an international audience of healthcare professionals only.

All trademarks are the property of their respective owners.

MAT-ES-XTD-2024-00462 | June 2024